{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:52:37Z","timestamp":1769561557665,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2016.01.035","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T17:30:33Z","timestamp":1457976633000},"page":"1342-1348","source":"Crossref","is-referenced-by-count":13,"title":["Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Masahiro","family":"Yasaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruyuki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(13)70079-6","article-title":"Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomized controlled trials","volume":"12","author":"Whiteley","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","article-title":"Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials","volume":"38","author":"Paciaroni","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0035","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0040","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0045","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000105682","article-title":"Early recurrence of ischemic stroke in Japanese patients: the Japan standard stroke registry study","volume":"24","author":"Toyoda","year":"2007","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0060","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1161\/01.STR.20.5.598","article-title":"Hemorrhagic transformation in cerebral embolism","volume":"20","author":"Okada","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0065","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1161\/STROKEAHA.106.480475","article-title":"Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke","volume":"38","author":"Lansberg","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0070","first-page":"24","article-title":"Predictors for hemorrhagic transformation with intravenous tissue plasminogen activator in acute ischemic stroke","volume":"38","author":"Moriya","year":"2013","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0075","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/archinte.1987.00370040018003","article-title":"Cardioembolic stroke, early anticoagulation, and brain hemorrhage","volume":"147","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0080","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/STROKEAHA.114.005339","article-title":"Stroke prevention in Asian patients with atrial fibrillation","volume":"45","author":"Yasaka","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0085","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1161\/STROKEAHA.114.006661","article-title":"Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin","volume":"45","author":"Hagii","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0090","doi-asserted-by":"crossref","first-page":"e11364","DOI":"10.1371\/journal.pone.0113641","article-title":"Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan","volume":"9","author":"Okata","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0100","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0105","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0110","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ijs.12452","article-title":"Trends in oral anticoagulant choice for acute stroke with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF Study","volume":"10","author":"Toyoda","year":"2015","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jns.2013.05.016","article-title":"Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation","volume":"331","author":"Shibazaki","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jstrokecerebrovasdis.2016.01.035_bib0120","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijs.12386","article-title":"Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation","volume":"10","author":"Hong","year":"2015","journal-title":"Int J Stroke"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305716000628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305716000628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T10:20:10Z","timestamp":1536920410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305716000628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1052305716000628"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2016.01.035","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}